A Phase II Study of Amivantamab SC subcutaneous in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer Lung-MAP Sub-Study?

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT06116682

Study #:
STUDY00161358

Start Date:
Mar 21, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06116682

View Complete Trial Details & Eligibility at ClinicalTrials.gov